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Abstract
Background: Tuberculosis, bacterial community-acquired pneumonia (CAP), and Pneumocystis jirovecii pneumonia
(PJP) are the three commonest causes of hospitalisation in HIV-infected adults. Prompt diagnosis and treatment
initiation are important to reduce morbidity and mortality, but are hampered by limited diagnostic resources in
resource poor settings. C-reactive protein (CRP) and procalcitonin have shown diagnostic utility for respiratory tract
infections, however few studies have focussed on their ability to distinguish between tuberculosis, CAP, and PJP in
HIV-infected inpatients.
Methods: We evaluated the diagnostic accuracy of CRP and procalcitonin, compared with composite reference
standards, to discriminate between the three target infections in adult HIV-infected inpatients in two district level
hospitals in Cape Town, South Africa. Participants were admitted with current cough and danger signs in
accordance with the WHO algorithm for tuberculosis in seriously ill HIV-infected patients. Study clinicians were
blinded to CRP and procalcitonin results.
Results: Two hundred forty-eight participants met study case definitions: 133 with tuberculosis, 61 with CAP, 16
with PJP, and 38 with mixed infection. In the 210 particpants with single infections the differences in median CRP
and procalcitonin concentrations between the three infections were statistically significant, but distributions
overlapped considerably. CRP and procalcitonin concentrations were highest in the CAP group and lowest in the
PJP group. CRP and procalcitonin cut-offs with sensitivities of ≥90% were found for all three target infection pairs,
but corresponding specificities were low. Highest receiver operating characteristic areas under the curve for CRP
and procalcitonin were for PJP versus tuberculosis and PJP versus CAP (0.68 and 0.71, and 0.74 and 0.69
respectively).
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Conclusions: CRP and procalcitonin showed limited value in discriminating between the three target infections due
to widely overlapping distributions, but diagnostic accuracy was higher for discriminating PJP from CAP or tuberculosis.
Our findings show limitations for CRP and procalcitonin, particularly for discriminiation of tuberculosis form CAP,
however they may have greater diagnostic utility as part of a panel of biomarkers or in clinical prediction rules.
Keywords: HIV, Tuberculosis, Bacterial community-acquired pneumonia, Pneumocystis jirovecii pneumonia, C-reactive
protein, Procalcitonin, Diagnostic accuracy, WHO algorithm
Background
Respiratory infections are a major cause for hospital admis-
sion in HIV-infected people globally in the antiretroviral
era; the commonest being tuberculosis, bacterial
community-acquired pneumonia (CAP), and Pneumocystis
jirovecii pneumonia (PJP) [1]. Prompt diagnosis and initi-
ation of appropriate treatment is important to reduce mor-
tality in HIV-infected inpatients.
Determining the aetiology of serious infections in inpa-
tients with HIV is challenging, in part due to considerable
overlap in the clinical and radiographic presentation of tu-
berculosis, CAP, and PJP [2]. Atypical presentation and dual
infection further compound these diagnostic challenges.
Furthermore, there are limitations of current diagnostic
methods and limited access to diagnostic tests in resource
poor settings [3–5].
WHO’s algorithm for the diagnosis of tuberculosis in
seriously ill patients [6] recommends broad spectrum
antibiotics, that treatment for PJP should be considered
(without giving guidance on selection of patients for em-
piric PJP therapy), using a rapid nucleic acid amplifica-
tion test (the Xpert MTB/RIF assay) to diagnose
tuberculosis, and empiric therapy for tuberculosis if the
Xpert MTB/RIF assay is negative or unavailable, and
there is no response to antibiotics. Our group recently
reported that 91.5% of patients defined as seriously ill by
WHO and who had a current cough were diagnosed
with tuberculosis, CAP, and/or PJP [7]. Incorporating
simple affordable tests in clinical algorithms to discrim-
inate between these three infections could improve out-
comes in seriously ill patients. Two inflammatory
biomarkers, C-reactive protein (CRP) and procalcitonin,
have shown some diagnostic utility for bacterial respira-
tory infections [8, 9], and CRP has high sensitivity but
low specificity for diagnosing HIV-associated tubercu-
losis [8]. An additional advantage is that both CRP and
procalcitonin are available as affordable point-of-care
tests [10, 11]. However, only two studies have examined
diagnostic performance of CRP in discriminating be-
tween tuberculosis, CAP, and PJP in hospitalised patients
with HIV, with conflicting results [2, 13]. We were un-
able to find any studies reporting diagnostic accuracy of
procalcitonin in discriminating between all three
infections.
The purpose of this study was to explore the diag-
nostic accuracy of CRP and procalcitonin in predict-
ing presence or absence of each of the three major
infections in seriously ill, HIV-infected inpatients.
Secondary objectives were to describe the extent to
which CRP and procalcitonin concentrations differed
between the three infections and to determine opti-
mal concentration cut-offs for discriminating those
with and without each target infection.
Methods
Study setting and participants
We conducted a secondary analysis of a data from a
large prospective cohort study [7], which was de-
signed to improve the evidence base for the WHO
algorithm for the diagnosis of tuberculosis in ser-
iously ill HIV-infected participants with current
cough [3]. Recruitment for the main study took place
at two secondary level hospitals in Cape Town, South
Africa, serving communities with high HIV and tu-
berculosis prevalence: G.F. Jooste District Hospital
from November 2011 until the hospital’s closure in
February 2013, and Khayelitsha District Hospital
from March 2013 until October 2014.
Inclusion criteria for the main study were: admis-
sion into the enrollment facility within the previous
24 h, ≥18 years of age, known HIV infection, cough
of any duration, and at least one WHO-defined dan-
ger sign (respiratory rate > 30/min, fever > 39o C,
pulse rate > 120/min, and unable to walk unaided).
Exclusion criteria were: anti-tuberculosis treatment
that was current, completed in the previous month,
or defaulted in the past 6 months (isoniazid prevent-
ive therapy was allowed); exacerbation of either con-
gestive cardiac failure or chronic obstructive
pulmonary disease; and failure to provide a spontan-
eous or induced sputum specimen.
For the current study we added the inclusion criter-
ion of a CRP and procalcitonin result, (funding for
these two assays only became available after the start
of the main study). We also only included partici-
pants fulfilling our a priori case definitions for tuber-
culosis, CAP, and/or PJP.
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Case definitions
Tuberculosis: positive Mycobacterium tuberculosis cul-
ture from any site plus at least one symptom consistent
with tuberculosis (cough, fever, night sweats, weight
loss). CAP: cough ≤14 days plus one or more additional
respiratory symptoms (sputum, breathlessness, chest
pain, haemoptysis or fever) plus radiological evidence of
pulmonary consolidation (confirmed by a radiologist)
[14]. PJP: cough ≤ 3 months plus radiological evidence
of diffuse bilateral interstitial infiltrates (confirmed by a
radiologist) plus oxygen saturation ≤ 92% (adapted from
Centers for Disease Control and Prevention case defin-
ition) [15].
Investigations
Three sputum specimens were obtained from each par-
ticipant. One sample was sent for Gram stain, culture,
and sensitivity, and two samples for smear examination
with auramine staining for acid-fast bacilli (AFB) and li-
quid mycobacterial culture (BACTEC™ MGIT™ 960; Bec-
ton, Dickinson and Company, New Jersey, USA).
Mycobaterial blood culture was done on all participants.
Mycobacterial culture was done on other specimens
when appropriate (e.g. pleural fluid).
CRP (Siemens Advia 1800), procalcitonin (Siemens
Advia Centaur XP), and β-D-glucan assay (Fungitell™;
Associates of Cape Cod, Inc., east Falmouth, MA, USA)
were done on stored serum in a batch after the study,
therefore these tests had no role in patient management.
Laboratory staff were blinded to participant diagnosis
and outcome. Assay range for CRP was 4-[304–336]
mg/L, normal range was below 10 mg/L. Assay range for
procalcitonin was < 0.02–75 μg/L, normal range below
0.02 μg/L.
Chest radiographs were performed on admission and
retrospectively reviewed by a senior radiologist blinded
to diagnoses and results of laboratory investigations.
Statistical analyses
All analyses were performed using Stata software version
13.0 (StataCorp Inc., College Station, Texas, USA).
Based on our fixed sample size of 210 participants
with single respiratory infections, we explored precision
to detect 90% sensitivity for each biomarker for the three
target infections, aiming for a maximum ±10% variation
in 95% confidence intervals (CIs). We estimated a range
of CIs of binomial proportions using the Wilson-score
interval for smaller sample sizes [16]. Since our data was
not normally distributed, a second calculation was made
using 85% of the original sample sizes as suggested by
Lehmann et al. [17]. We estimated the 95% CIs of 90%
sensitivity to be 83–94% for tuberculosis, 79–96% for
CAP, and 69–99% for PJP. The small sample size for PJP
accounted for wide 95% confidence intervals. Further
details of these sample size calculations are provided in
an additional table (see Additional file 1: Table S1).
To detect differences in CRP concentrations be-
tween the three target infections, we estimated power
for a two-sample means test (assuming unequal vari-
ances), based on relevant literature. (Expected means
for CRP were approximate due to lack of reported
standard deviations for tuberculosis or CAP). Our
study had 80% power and alpha of 0.05 (using 85% of
the original sample size to account for non-normal
distribution of CRP and procalcitonin concentrations)
to detect a minimum mean concentration difference
in CRP between tuberculosis and PJP of 36%, between
CAP and PJP of 14%, and between CAP and tubercu-
losis of 14%, and a minimum mean concentration dif-
ference in procalcitonin of 50% between tuberculosis
and PJP, 62% between CAP and PJP, and 62% between
CAP and tuberculosis. We were unable to find data
on sensitivity estimates for procalcitonin in all three
target infections in HIV-infected individuals, therefore
calculations were based exclusively on studies report-
ing CRP measures of diagnostic accuracy. Further de-
tails of these sample size calculations are provided in
an additional table (see Additional file 1:, Table S2).
Diagnostic accuracy analyses for CRP and procalcito-
nin were performed for participants fulfilling criteria for
one of the three single infection definitions. Participants
with mixed infection were analysed separately. In clinical
practice, differential diagnostic challenges usually
present between two of the target infections and less
commonly between all three, hence we calculated diag-
nostic accuracy measures between infection pairs in
addition to each target infection versus the other two.
As distributions of both CRP and procalcitonin were
not normally distributed, we used non-parametric statis-
tical tests for continuous variables. Univariate associations
between participant baseline characteristics in infection
pairs were analysed using the Wilcoxon-Mann-Whitney
test for continuous data, and Chi-square test (or Fisher’s
Exact test if values in a cell were < 5), for categorical data.
All probability tests were two-tailed. CRP and procalcito-
nin values below the detectable limit (BDL) of the assay
were substituted with half BDL (in preference to substitu-
tion with the assay limit or with zero, both of which have
been shown to bias parameter estimates) [18].
Receiver Operating Characteristic (ROC) area under
the curve (AUC) analyses were used to explore potential
cut-offs for CRP for each target infection using Liu’s
index [19], which we then used to calculate diagnostic
accuracy estimates. Cut-offs were also explored using
the WHO 90% sensitivity recommendation for screening
tests for tuberculosis [20]. To mitigate overfitting and
improve accuracy of model prediction, we performed
cross-validation on all ROC AUC’s exceeding 60% using
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k-fold cross-validation, as the dataset was too small for
generation of a training set.
Since there are few studies on the diagnostic accur-
acy of procalcitonin for infections in HIV-infected pa-
tients, we explored cut-offs established for both lower
respiratory tract infections (LRTI) and sepsis. Procal-
citonin categories for LRTI were: < 0.1 μg/L, bacterial
infection very unlikely; 0.1–0.25 μg/L, localised bac-
terial infection unlikely; 0.25–0.5 μg/L, localised bac-
terial infection possible; > 0.5 μg/L, suggestive of
bacterial infection. Procalcitonin categories for sys-
temic bacterial infection / sepsis were: 0.5–2 μg/L,
systemic infection possible; 2–10 μg/L, suggestive of
systemic infection; > 10 μg/L, severe systemic infec-
tion / septic shock [9].
This study conforms to the Standards for Reporting
Diagnostic Accuracy Studies (STARD) guidelines [21].
Results
Participant characteristics
The participant flow diagram is shown in Fig. 1. Ten
participants were excluded due to diagnoses other than
the three target infections (meningitis, disseminated
Cryptococcus, emmonsia, bronchitis, and post-TB bron-
chiectasis with a pneumothorax). All participants had re-
ceived at least one dose of antibiotics as per WHO
Fig. 1 Consort diagram based on Standards for Reporting Diagnostic Accuracy Studies (STARD)
Mendelson et al. BMC Infectious Diseases  (2018) 18:399 Page 4 of 11
guidelines (usually ceftriaxone) prior to obtaining blood
samples used for biomarker tests. 73/248 (29%) reported
taking cotrimoxazole prophylaxis prior to admission.
Figure 2 summarises the distribution of target infections
in all 248 participants.
Baseline characteristics of the 210 paticipants with one
of the three single infection diagnoses (i.e. excluding par-
ticipants with mixed infection) are shown in Table 1.
Tuberculosis was associated with lower haemoglobin
concentrations and reported weight loss compared with
the other two groups. Inability to walk unaided was
more common in those with tuberculosis than in those
with CAP. Those with CAP had higher median white
cell count and CD4 count than the other two infections.
The CAP group was more likely to have been using anti-
retroviral therapy prior to admission compared with the
tuberculosis group. Participants with PJP were much
more likely to have β-D-glucan concentrations exceeding
300 pg/L, had lower CD4 counts, and were more likely
to have a respiratory rate above 30/min than participants
in the other two groups.
CRP concentrations and diagnostic utility for each
infection
Distributions of CRP concentrations by single infection
category are shown in Fig. 3a. Comparison of CRP con-
centrations between the three single infections are
shown in Table 2. Elevated CRP concentrations (>
10 mg/L) were found in 206/210 (98%) participants:
131/133 (98%) with tuberculosis, 60/61 (99%) with CAP,
and 15/16 (94%) with PJP. There were statistically sig-
nificant differences in median concentrations between
infection pairs, with considerable overlap in distribu-
tions. The highest concentrations were in participants
with CAP and the lowest concentrations in those with
PJP.
ROC AUCs for CRP for each single infection pair are
shown in Fig. 4. Cross-validation showed minor reduc-
tions of ROC AUCs: from 0.60 to 0.58 (95% CI: 0.49–
0.67) in the tuberculosis versus CAP group; from 0.74 to
0.72 (95% CI: 0.59–0.84) for CAP versus PJP; and from
0.68 to 0.64 (95% CI: 0.51–0.77) for PJP versus tubercu-
losis. Diagnostic accuracy estimates for two cut-offs for
each infection pair and each infection versus the other
two infections are presented in Table 3. CRP cut-offs
with reasonable diagnostic accuracy were found for PJP
versus CAP, PJP versus tuberculosis and PJP versus the
other two infections.
Procalcitonin concentrations and diagnostic utility for
each infection
Distributions of procalcitonin category in each of the
three target infections are shown in Fig. 3b and Table 2.
We found highest procalcitonin concentrations in the
CAP group and lowest in those with PJP. There were
statistically significant differences in median procalcito-
nin concentrations between the three infection groups,
but there was marked overlap in distributions. Diagnos-
tic performance of procalcitonin categories for discrim-
inating between infection pairs is shown in Table 4.
ROC AUCs for procalcitonin for each single infection
pair are shown in Fig. 4. Best performance of procalcito-
nin was in discriminating between CAP and PJP.
Participants with mixed infection
Analysis of baseline characteristics and biomarker con-
centrations for those with mixed infection compared
with those with single target infections are summarised
in an additional table (see Additional file 2). Analysis of
both biomarkers showed wide distributions, overlapping
with those of the three mono-infections. Elevated CRP
was found in all 38 participants with mixed infections.
Both CRP and procalcitonin medians were statistically
higher in the mixed infection group compared with the
PJP group. Three participants had procalcitonin concen-
trations < 0.1 μg/L, all of whom had CAP dual infection
(two with tuberculosis and the other with PJP). Procalci-
tonin ≥0.25 μg/L captured 29/37 (78.4) with CAP dual
infection, ≥ 0.5 μg/L captured 23/37 (62.2%), and 14
(37.8%) exceeded the ≥2 μg/L cut-off, 3 of whom had
concentrations above 10 μg/L.
Discussion
We evaluated the diagnostic accuracy of CRP and procalci-
tonin for differentiating between the three major infections
affecting HIV-infected adult inpatients. Our study is one of
Fig. 2 Venn diagram of number of participants diagnosed with
single target infections and mixed infections. Numbers in
parentheses are %
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only a very few to assess the diagnostic accuracy of CRP
and procalcitonin for the three commonest infections in
HIV-infected inpatients. We found statistically significant
differences in median CRP and procalcitonin concentra-
tions between the three infection groups, but there was
marked overlap in distributions. Participants with PJP had
lower CRP and procalcitonin concentrations. Procalcitonin
and CRP had ROC AUCs of around 0.7 for discriminating
PJP from CAP and tuberculosis in pairwise comparisons,
indicating moderate discrimination, but both bio-
markers performed less well in discriminating CAP
from tuberculosis. A CRP cut-off of 147 mg/L had
high specificity for discriminating PJP from CAP, and
high sensitivity for discriminating PJP from tubercu-
losis. We found cut-offs with sensitivities of 90% or
more for CRP for all three target infection pairs, and
for procalcitonin for two target infection pairs (tuber-
culosis versus PJP and CAP versus PJP), but specific-
ities were much lower than the 70% recommended by
WHO for tuberculosis screening tests [20]. Our find-
ings suggest that CRP and/or procalcitonin should be
explored in the development of clinical prediction
Table 1 Baseline characteristics of 210 participants with a single target infection by infection status
Diagnosis n (%) Total N =
210
TB n = 133
(63)
CAP n = 61
(29)
PJP n = 16
(8)
P-value for pairwise comparisona
Median age in yrs.
(IQR)
34.8
(28.9–40.7)
34.7
(29.1–40.8)
35.1
(29.4–40.0)
36.9
(28.8–41.2)
TB vs. CAP: 0.96, CAP vs. PJP: 0.84
PJP vs. TB: 0.75
Sex: female n(%) 139 (66) 84 (63) 44 (72) 11 (69) TB vs. CAP: 0.22, CAP vs. PJP: 0.71b
PJP vs. TB: 0.79b
Cotrimoxazole
prophylaxis
60 (29) 38 (29) 18 (30) 4 (25) TB vs. CAP: 0.89, CAP vs. PJP: 0.49b
PJP vs. TB: 1.00b
Antiretroviral therapy
n (%)
76 (36) 43 (32) 29 (48) 4 (25) TB vs. CAP: 0.04, CAP vs. PJP: 0.16b
PJP vs. TB: 0.78b
Median CD4+ count,
cells/μL (IQR)
97 (38–210) 77 (35–162) 200 (79–287) 35 (12–81) TB vs. CAP: 0.0001
CAP vs. PJP: 0.0005, PJP vs. TB: 0.03
Median WCC ×109/L
(IQR)
8.6 (5.8–
12.9)
7.3 (5.2–10.2) 12.3 (8.4–20.0) 8.2 (6.2–10.7) TB vs. CAP: 0.0001, CAP vs. PJP: 0.01
PJP vs. TB: 0.5
Median Hb g/dL (IQR) 9.4 (7.7–
10.8)
8.6 (7.4–10.1) 10.4 (8.8–12) 11.25
(9.7–12.2)
TB vs. CAP: 0.0001, CAP vs. PJP: 0.24
PJP vs. TB: 0.0001
β-D-glucan > 300 pg/mL 25 (12) 11 (8) 1 (2) 13 (80) TB vs. CAP: 0.11b, CAP vs. PJP: < 0.0001b PJP vs. TB: <
0.0001b
WHO danger signsc:
Pulse rate >
120 beats/min
166 (79) 106 (80) 51 (84) 9 (56) TB vs. CAP: 0.52, CAP vs. PJP: 0.02
PJP vs. TB: 0.04
Respiratory rate >
30/min
137 (65) 83 (62) 38 (62) 16 (100) TB vs. CAP: 0.99, CAP vs. PJP: 0.002b
PJP vs. TB: 0.001b
Fever> 39 °C 31 (15) 20 (15) 10 (16) 1 (6) TB vs. CAP: 0.81, CAP vs. PJP: 0.44b
PJP vs. TB: 0.47b
Unable to walk
unaided
119 (57) 88 (67) 23 (38) 8 (50) TB vs. CAP:< 0.0001, CAP vs. PJP: 0.40
PJP vs. TB: 0.19
TB symptomsd:
Night sweats 137 (66) 89 (67) 38 (63) 10 (67) TB vs. CAP: 0.58, CAP vs. PJP:1.00b
PJP vs. TB: 0.78b
Weight loss 196 (94) 130 (98) 53 (88) 13 (81) TB vs. CAP: 0.005b, CAP vs. PJP: 0.43b
PJP vs. TB: 0.009b
Fever 170 (82) 106 (80) 52 (87) 12 (75) TB vs. CAP: 0.29, CAP vs. PJP: 0.27b
PJP vs. TB: 0.74b
Abbreviations: TB tuberculosis, CAP bacterial community-acquired pneumonia, PJP Pneumocystis jirovecii pneumonia, Hb haemoglobin, WCC white cell count
aHypothesis tests- Wilcoxon-Mann-Whitney test for continuous data; Chi-square test for categorical data. bFisher’s exact test where 1 or more cells < 5
cDanger signs based on WHO algorithm for diagnosis of TB in seriously ill patients; d Cough of any duration was a study inclusion criterion
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rules in seriously ill HIV-infected patients or in a panel of
biomarkers rather than be used as stand alone diagnostic
tests.
Previous studies have demonstrated the diagnostic value
of CRP in active tuberculosis case detection in otherwise
healthy HIV-infected persons, however higher false posi-
tive rates were found in passive case detection [8]. Ele-
vated CRP is known to occur in all three of our target
infections in individuals with HIV, and our finding that
CRP concentrations were highest in CAP, follwed by tu-
berculosis, and lowest in PJP, is consistent with previous
studies [12, 13, 22]. We found that diagnostic performance
of CRP in our study population was limited by widely
overlapping distributions between the three target infec-
tions, resulting in reduced utility for inpatient populations
where these are the three commonest competing aetiol-
ogies. Similar low specificity for discriminating between all
three infections was shown in a British case notes review
Fig. 3 Distribution of (a) C-reactive protein and (b) procalcitonin in the 210 participants with single infections
Table 2 C-reactive protein and procalcitonin distributions by infection in 210 participants with a single target infection
Biomarker concentration Total (N = 210) TB (n = 133) CAP (n = 61) PJP (n = 16) P-value c
Median CRP mg/L (IQR) 148 (96–224) 141 (97–203) 193 (108–264) 106.5 (79.5–131.5) TB vs.CAP: 0.02, CAP vs. PJP: 0.003
PJP vs. TB: 0.02
CRP≥ 10 mg/La n (%) 206 (98) 131 (98.5) 60 (98.4) 15 (93.8) TB vs.CAP: 1.00d, CAP vs. PJP: 0.38d
PJP vs. TB: 0.29d
Median PCT μg/L (IQR) 0.8 (0.3–2.9) 0.7 (0.4–2.1) 2.0 (0.4–5.2) 0.2 (0.1–1.3) TB vs. CAP: 0.05, CAP vs. PJP: 0.01
PJP vs. TB: 0.05
PCT≥ 0.02 μg/Lb: n (%) 209 (99.5) 132 (99) 61 (100) 16 (100) –
PCT≥ 0.1 μg/L: n (%) 199 (94.8) 128 (96.2) 58 (95.1) 13 (81.3) TB vs. CAP: 0.71d,, CAP vs. PJP: 0.10d
PJP vs. TB: 0.04d
PCT≥ 0.25 μg/L: n (%) 170 (81) 112 (84) 50 (82) 8 (50) TB vs. CAP: 0.70, CAP vs. PJP: 0.008
PJP vs: TB: 0.001
PCT≥ 0.5 μg/L: n (%) 137 (65.2) 87 (65.4) 43 (70.5) 7 (43.8) TB vs. CAP: 0.49, CAP vs. PJP: 0.05
PJP vs. TB: 0.11
PCT≥ 2 μg/L: n (%) 69 (32.9) 36 (27.1) 30 (49.2) 3 (18.8) TB vs. CAP: 0.003, CAP vs. PJP: 0.05d
PJP vs. TB: 0.56d
PCT > 10 μg/L: n (%) 16 (8) 8 (6) 8 (13) 0 (0) –
Abbreviations: CRP C-reactive protein, PCT Procalcitonin, TB tuberculosis, CAP bacterial community-acquired pneumonia, PJP Pneumocystis jirovecii pneumonia
aElevated concentration. bLower detectable limit for procalcitonin assay
cHypothesis tests- Wilcoxon-Mann_Whitney test for non-normally distributed continuous data and Chi-square test for categorical data
dFisher’s exact test where 1 or more cells < 5
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study of HIV-infected adults admitted with respiratory in-
fections [13]. Conversely, our findings differed from a pre-
vious South African study that reported good
discrimintaion of CRP (ROC AUC of 0.87) when compar-
ing participants with pneumococcal community-acquired
pneumonia and pulmonary tuberculosis [22]. We suspect
that the disparity may be attributable to differences in par-
ticipant selection or to the small sample size in the other
South African study. Another study found specificity (83%)
and sensitivity 69%, for combined CRP and IL-8 for dis-
criminating bacerial pneumonia from PJP or mycobaterio-
sis, in a cohort that included hospital-acquired infections
and non-tuberculous mycobacterial infections [12].
Guidelines for procalcitonin suggest that bacterial infec-
tion is present at a concentration of ≥0.25 μg/L [9]. Al-
though this cut-off captured 82% of participants with CAP
in our study, it also identified 84% of those with tubercu-
losis and 50% of those with PJP; therefore had limited
value in distinguishing CAP from the other two infections.
Procalcitonin distribution across the three infections in
our cohort, with concentrations highest in CAP and low-
est in PJP, were comparable to other studies in
HIV-infected individuals [22, 23]. However, our findings
did not mirror those of two other studies of inpatients
with mixed HIV status, both of which found little overlap
in procalcitonin concentrations between any of the three
target infections [22, 23]. In Schleicher’s study, elevated
procalcitonin (> 0.1 μg/L) was found in all participants
with bacterial pneumonia and only 59% of the tuberculosis
group, compared with 95% and 96% respectively in our
study. Schleicher et al. and Lawn et al. noted a possible
link between raised procalcitonin and lower CD4 count
[20, 22]; in our participants with tuberculosis as a single
infection we also found a moderate negative association
between CD4 count and procalcitonin (Spearman’s rho −
0.33, p-value = 0.0001). Differing CD4 count medians (107
in Schleicher’s cohort compared with 77 × 109 cells/L in
ours) tuberculosis versus PJP and CAP versus PJP may
Fig. 4 ROC curves for C-reactive protein and procalcitonin for single infection pairs. a Tuberculosis versus bacterial community-acquired
pneumonia, (b) bacterial community-acquired pneumonia versus Pneumocystis jirovecii pneumonia, and (c) Pneumocystis jirovecii pneumonia
versus tuberculosis
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account for higher procalcitonin concentrations in our tu-
berculosis group.
Mixed infection is a well-recognised limitation in diag-
nostic accuracy studies. Our study prevalence of 15.3%
mixed infection compared to Nyamande’s reported 21%
[23]. In our study, elevated CRP was found in all 38 partici-
pants with mixed infection and elevated procalcitonin in
92%. Our participants with mixed infection had higher me-
dian concentrations of both CRP and procalcitonin than
the participants with tuberculosis and PJP as single infec-
tions, but statistical significance was only found when com-
paring mixed infection to PJP as a single infection. Due to
the difficulty in determining the extent of contribution of
each infection to biomarker concentrations, the mixed infec-
tion group was excluded from diagnostic accuracy analyses.
Our study has a number of limitations. First, reference
standards for CAP and PJP did not include microbio-
logical confirmation. Although blood and sputum cultures
were carried out to detect bacterial infections, almost all
were negative due to prior antibiotic use. However, even if
cultures had been taken prior to antibiotics the sensitivity
of sputum and blood cultures for CAP is low, and clinical
case definitions of CAP are universally used in clinical
research. Bronchoalveolar lavage, which is the optimal
specimen for diagnosing PJP, was not available at either of
our study hospitals. However, we adapted the CDC case
definition for PJP, which has a sensitivity and specificity of
85% for diagnosis of PJP when compared with bronchos-
copy [24]. Furthermore, we found β-D-glucan exceeding
300 pg/L in 80% of our participants fulfilling our PJP case
definition, compared with 8% for tuberculosis and 2% for
CAP. β-D-glucan had a sensitivity of 92% and a specificity
of 78% for the diagnosis of PJP in HIV-infected patients in
a systematic review [25], and 91% sensitivity and 92% spe-
cificity for a β-D-glucan cut-off > 300 pg/L in one study
[26]. Second, our sample size of participants with PJP was
small. Third, CRP and procalcitonin concentrations may
have been reduced in participants with bacterial infections
by antibiotic treatment prior to providing a blood spe-
cimen at study enrolment, which would reduce the
ability of the biomarkers to discriminate CAP from
TB and PJP. However, this is unlikely to have had a
major effect as almost all of our participants re-
ceived antibiotics within 24 h of study enrolment.
Study strengths include the use of a robust culture-based
reference standard for tuberculosis and that our study
Table 3 Diagnostic accuracy of C-reactive protein by infection pair in 210 participants with single target infections
Infectiona Cut-off (mg/
L)
Sensitivity% (95%
CI)
Specificity% (95%
CI)
PPV%
(95% CI)
NPV%
(95% CI)
LR+ (95%
CI)
LR- (95%
CI)
Diagnostic odds ratio
(95% CI)
TB vs. CAP CRP ≥64 90.2 (83.9–94.7) 11.5 (4.7–22.2) 69.0
(61.5–75.7)
35.0
(15.4–59.2)
1.02
(0.92–1.13)
0.85
(0.36–2.03)
1.20 (0.45–3.17)
CRP < 175 65.4 (56.7–73.4) 57.4 (44.1–70.0) 77.0
(68.1–84.4)
43.2
(32.2–54.7)
1.53
(1.12–2.11)
0.60
(0.44–0.83)
2.55 (1.37–4.72)
CAP vs. PJP CRP≥ 63 90.2 (79.8–96.3) 18.8 (4.0–45.6) 80.9
(69.5–89.4)
33.3
(7.5–70.1)
1.11
(0.86–1.42)
0.52
(0.15–1.87)
2.12 (0.51–8.94)
CRP≥ 147 63.9 (50.6–75.8) 87.5 (61.7–98.4) 95.1
(83.5–99.4)
38.9
(23.1–56.5)
5.11
(1.38–18.96)
0.41
(0.28–0.60)
12.41 (2.83–59.7)
PJP vs. TB CRP ≥33 93.8 (69.8–99.8) 2.3 (0.5–6.5) 10.3
(5.9–16.5)
75.0
(19.4–99.4)
0.96
(0.84–1.09)
2.77
(0.31–25.08)
0.35 (0.03–3.54)
CRP < 147 87.5 (61.7–98.4) 48.9 (40.1–57.7) 17.1 (9.7–
27.0)
97.0
(89.6–99.6)
1.71
(1.33–2.19)
0.26
(0.07–0.95)
6.69 (1.46–30.60)
TB vs. CAP/
PJP
CRP ≥64 90.2 (83.9–94.7) 13.0 (6.4–22.6) 64.2
(56.8–71.0)
43.5
(23.2–65.5)
1.04
(0.94–1.15)
0.75
(0.35–1.63)
1.38 (0.58–3.25)
CRP ≥150 48.9 (40.1–57.7) 49.4 (37.8–61.0) 62.5
(52.5–71.8)
35.8
(26.8–45.7)
0.96
(0.73–1.28)
1.04
(0.78–1.37)
0.93 (0.53–1.63)
CAP vs. TB/
PJP
CRP ≥63 90.2 (79.8–96.3) 10.7 (6.3–16.9) 29.3
(22.9–36.3)
72.7
(49.8–89.3)
1.01
(0.91–1.12)
0.92
(0.38–2.23)
1.10 (0.42–2.87)
CRP ≥175 57.4 (44.1–70.0) 67.8 (59.6–75.2) 42.2
(31.4–53.5)
79.5
(71.5–86.2)
1.78
(1.30–2.45)
0.63
(0.46–0.86)
2.83 (1.54–5.21)
PJP vs. TB/
CAP
CRP ≥33 93.8 (69.8–99.8) 2.6 (0.8–5.9) 7.4
(4.2–11.8)
83.3
(35.9–99.6)
0.96
(0.85–1.09)
2.42
(0.30–19.52)
0.40 (0.04–3.62)
CRP < 147 87.5 (61.7–98.4) 53.6 (46.3–60.8) 13.5
(7.6–21.6)
98.1
(93.4–99.8)
1.89
(1.48–2.40)
0.23
(0.06–0.86)
8.09 (1.99–36.55)
Two cut-offs are listed for each infection pair and one infection versus the other two: the first with minimum 90% sensitivity and the second selected using the
Liu index (see text for details)
Abbreviations: TB tuberculosis, CAP bacterial community-acquired pneumonia, PJP Pneumocystis jirovecii pneumonia, PPV positive predictive value, NPV negative
predictive value, LR Likelihood ratio, CI confidence interval. a Cohort prevalences: TB, 63.3% (95%CI, 56.4–69.9%); CAP, 29.0% (95% CI, 23.0–35.7%); PJP, 7.6% (95%
CI, 4.4–12.1%)
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participants were recruited from two urban district hospi-
tals that represent a population typical of high HIV and tu-
berculosis burden settings.
Conclusions
CRP and procalcitonin were both found to have limited
value in distinguishing between the three common infections
due to widely overlapping distributions, particularly between
tuberculosis and CAP. Future studies should include a larger
sample of participants with PJP definitively diagnosed, as
both biomarkers had best diagnostic accuracy for discrimin-
ating between PJP and the other two infections in our study.
CRP and procalcitonin may have greater diagnostic utility as
part of a panel of biomarkers or in clinical prediction rules.
Additional files
Additional file 1: Power calculations. Table S1. Power calculation for
sensitivity estimates for each target infection. Table S2. Power calculation to
detect C-reactive protein and procalcitonin concentration differences between
target disease pairs (DOCX 19 kb)
Additional file 2: Baseline characteristics including participants with
mixed infection. (PDF 105 kb)
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Table 4 Diagnostic accuracy of procalcitonin by infection pair in 210 participants with single target infections
Infection paira Cut-off
(μg/L)
Sensitivity%
(95% CI)
Specificity%
(95% CI)
PPV%
(95% CI)
NPV%
(95% CI)
LR+ LR- Diagnostic odds ratio
(95% CI)
TB vs. CAP PCT≥ 0.1 96.2
(91.4–98.8)
4.9 (1.0–13.7) 68.8
(61.6–75.4)
37.5 (8.5–75.5) 1.01
(0.95–1.08)
0.76 (0.19–3.10) 1.32 (0.34–5.21)
PCT≥ 0.25 84.2
(76.9–90.0)
18.0 (9.4–30.0) 69.1
(61.4–76.1)
34.4
(18.6–53.2)
1.03
(0.89–1.18)
0.88 (0.45–1.70) 1.17 (0.53–2.59)
PCT≥ 0.5 65.4
(56.7–73.4)
29.5
(18.5–42.6)
66.9
(58.1–74.9)
28.1
(17.6–40.8)
0.93
(0.76–1.14)
1.17 (0.75–1.84) 0.79 (0.41–1.52)
PCT≥ 2 27.1
(19.7–35.5)
50.8
(37.7–63.9)
54.5
(41.8–66.9)
24.2
(17.1–32.6)
0.55
(0.38–0.80)
1.44 (1.10–1.88) 0.38 (0.20–0.72)
PCT > 10b 6.0 (2.6–11.5) 86.9
(75.8–94.2)
50.0
(24.7–5.3)
29.8
(23.2–37.1)
0.46
(0.18–1.16)
1.08 (0.97–1.20) 0.42 (0.16–1.15)
CAP vs. PJP PCT≥ 0.1 95.1
(86.3–99.0)
18.8 (4.0–45.6) 81.7
(70.7–89.9)
50.0
(11.8–88.2)
1.17
(0.92–1.49)
0.26
(0.06–1.180
4.46 (0.92–21.84)
PCT≥ 0.25 82.0
(70.0–90.6)
50.0
(24.7–75.3)
86.2
(74.6–93.9)
42.1
(20.3–66.5)
1.64
(0.99–2.71)
0.36
(0.17–0.75)
4.55 (1.44–14.43)
PCT≥ 0.5 70.5
(57.4–81.5)
56.2
(29.9–80.2)
86.0
(73.3–94.2)
33.3
(16.5–54.0)
1.61
(0.90–2.87)
0.52
(0.29–0.94)
3.07 (1.02–9.26)
PCT≥ 2 49.2
(36.1–62.3)
81.2
(54.4–96.0)
90.9
(75.7–98.1)
29.5
(16.8–45.2)
2.62
(0.92–7.51)
0.63
(0.44–0.88)
4.19 (1.15–15.03)
PJP vs. TB PCT≥ 0.1 81.2
(54.4–96.0)
3.8 (1.2–8.6) 9.2 (5.0–15.3) 62.5
(24.5–91.5)
0.84
(0.67–1.07)
4.99
(1.31–18.94)
0.17 (0.04–0.71)
PCT≥ 0.25 50.0
(24.7–75.3)
15.8
(10.0–23.1)
6.7 (2.9–12.7) 72.4
(52.8–87.3)
0.59
(0.36–0.97)
3.17
(1.69–5.93)
0.19 (0.07–0.54)
PCT≥ 0.5 43.8 (19.8–70.1) 34.6 (26.6–43.3) 7.4 (3.0–14.7) 83.6 (71.2–92.2) 0.67 (0.38–1.18) 1.63 (1.00–2.66) 0.41 (0.15–1.14)
PCT≥ 2 18.8 (4.0–45.6) 72.9 (64.5–80.3) 7.7 (1.6–20.9) 88.2 (80.6–93.6) 0.69 (0.24–1.99) 1.11 (0.86–1.44) 0.62 (0.18–2.17)
Selected categories are based on assay guidelines developed for antibiotic use guidance in lower respiratory tract infections and sepsis (see text for details)
Abbreviations: TB tuberculosis, CAP bacterial community-acquired pneumonia, PJP Pneumocystis jirovecii pneumonia, PPV positive predictive value, NPV negative
predictive value, LR Likelihood ratio, CI confidence interval. aCohort prevalences: TB, 63,3% (95%CI, 56.4–69.9%); CAP, 29.0% (95% CI, 23.0–35.7%); PJP, 7.6% (95%
CI, 4.4–12.1%)
bAnalaysis of PCT category of > 10 was only performed in TB vs. CAP infection pairs as no PJP participants had PCT exceeding 10 μg/L
Mendelson et al. BMC Infectious Diseases  (2018) 18:399 Page 10 of 11
Ethics approval and consent to participate
The University of Cape Town’s Human Research Ethics Committee approved
the study protocol (reference 334/2011). All enrolled participants signed
informed consent. Confused participants were enrolled and given the option
to continue with participation once they were orientated. If they declined to
give consent their data was removed.
Consent for publication
Not applicable
Competing interests
MR is a BMC Editorial Borad member. The other authors declare that they
have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1School of Public Health and Family Medicine, University of Cape Town,
Cape Town, South Africa. 2Division of Clinical Pharmacology, Department of
Medicine, University of Cape Town, Cape Town, South Africa. 3Centre for
Infectious Diseases Research Initiative, Institute of Infectious Diseases &
Molecular Medicine, University of Cape Town, Cape Town, South Africa.
4Department of Infection & Population Health, Institute of Global Health,
University College London, London, UK. 5Department of Medicine, University
of Cape Town, Cape Town, South Africa. 6Division of Infectious Diseases and
HIV Medicine, Department of Medicine, University of Cape Town, Cape
Town, South Africa.
Received: 28 March 2018 Accepted: 1 August 2018
References
1. Ford N, Shubber Z, Meintjes G, Grinsztejn B, Eholie S, Mills EJ, et al. Causes
of hospital admission among people living with HIV world-wide: a
systematic review and meta-analysis. Lancet HIV. 2015;2(10):e438–44.
2. Feldman C, Brink AJ, Richards GA, Maartens G, Bateman ED. Management of
community-acquired pneumonia in adults. Working group of the South
African Thoracic Society. SAMJ. 2007;97(12):1296–306.
3. Chegou NN, Hoek KGP, Kriel M, Warren RM, Victor TC, Walzl G. Tuberculosis
assays: past, present and future. Expert Rev Anti-Infect Ther. 2011;9(4):457–69.
4. Trebucq A, Enarson DA, Chiang CY, Van Deun A, Harries AD, Boillot F, et al.
Xpert® MTB/RIF for national tuberculosis programmes in low-income countries:
when, where and how? Int J Tuberc Lung Dis. 2011;15(12):1567–72.
5. Garcia-Vazquez E, Marcos MA, Mensa J, de Roux A, Puig J, Font C, et al.
Assessment of the usefulness of sputum culture for diagnosis of
community-asquired pneumonia using the PORT predictive scoring system.
Arch Intern Med. 2004;164:1807–11.
6. World Health Organization. Consolidated guidelines on the use of
antiretroviral drugs for treating and preventing HIV infection.
Recommendations for a public health approach. Second edition.
http://www.who.int/hiv/pub/arv/arv-2016/en/ Accessed 4 Oct 2017.
7. Griesel R, Stewart A, van der Plas H, Sikhondze W, Rangaka MX, Nicol MP, et al.
Optimizing tuberculosis diagnosis in human immunodeficiency virus-infected
inpatients meeting the criteria of seriously ill in the World Health Organisation.
Clin Infect Dis. 2018;66:1419–26.
8. Yoon C, Chaisson LH, Patel SM, Allen IE, Drain PK, Wilson D, et al. Diagnostic
accuracy of C-reactive protein for active pulmonary tuberculosis: a meta-
analysis. Int J Tuberc Dis. 2017;21(9):1013–9.
9. Scheutz P, Chiappa V, Briel M, Greenwald L. Procalcitonin algorithms for
antibiotic therapy decisions. A systematic review of randomized controlled
trials and recommendations for clinical algorithms. Arch Intern Med. 2011;
171(15):1322–31.
10. Yoon C, Simitala FC, Atuhumoza E, Katende J, Mwebe S, Asege L, et al.
Point-of-care C-reactive protein-based tuberculosis screening for people
living with HIV: a diagnostic accuracy study. The Lancet online 2017.
https://doi.org/10.1016/S1473-3099(17)30488-7. Accessed 8 Dec 2017.
11. Corti C, Fally M, Fabricius-Bjerre A, Mortensen K, Jensen BN, Andreassen HF,
et al. Point-of-care procalcitonin test to reduce antibiotic exposure in
patients hospitalized with acute exacerbation of COPD. Int J Chron Obstruct
Pulmon Dis. 2016;11:1381–9.
12. Benito N, Moreno A, Filella X, Miro MJ, Gonzalez J, Pumarola P, et al.
Inflammatory responses in blood samples of human immunodeficiency
virus-infected patients with pulmonary infections. Clin Diagn Lab Immunol.
2004;11:608–14.
13. Sage EK, Noursadeghi M, Evans HE, Noursadeghi M, Parker SJ, Copas AJ, et
al. Prognostic value of C-reactive protein in HIV-infected patients with
Pneumocystis jirovecii pneumonia. Int J STD AIDS. 2010;21:288–92.
14. Scott JAG, Hall AJ, Muyodi C, Lowe B, Ross M, Chohan B, et al. Aetiology,
outcome, and risk factors for mortality among adults with acute pneumonia
in Kenya. Lancet. 2000;355:1225–30.
15. Centers for Disease Control. Revision of the CDC surveillance case definition
for Acquired Immunodeficiency Syndrome. Morbidity and mortality weekly
report. 1987; 36(suppl no1S): Appendix III p. 13S. https://www.cdc.gov/
mmwr/pdf/other/mmsu3601.pdf Accessed 10 Jan 2017.
16. Agresti A, Coull BA. Approximate is better than “exact” for interval
estimation of binomial proportions. Am Stat. 1998;52(2):119–26.
17. Lehmann EL. Nonparametrics: statistical methods based on ranks, revised.
Upper Saddle River: Prentice Hall, Inc; 1998. p. 76–81.
18. LaFleur B, Lee W, Merchant N. Statistical methods for assays with limits of
detection: serum bile acid as a differentiator between patients with normal
colons, adenomas, and colorectal cancer. J Carcinog. 2011;10:12. https://doi.
org/10.4103/1477-3163.79681.
19. Liu X. Classification accuracy and cut point selection. Stat Med. 2012;31:
2676–86. https://doi.org/10.1002/sim.4509.
20. World Health Organization. High-priority target product profiles for new
tuberculosis diagnostics: report of a concensus meeting. http://www.who.
int/tb/publications/tpp_report/en/ Accessed 16 Jun 2017.
21. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al.
For the STARD Group. STARD 2015: an updated list of essential items for
reporting diagnostic accuracy studies. BMJ. 2015;351:h5527.
22. Schleicher GK, Herbert V, Brink A, Martin S, Maraj R, Galpin JS, et al.
Procalcitonin and C-reactive protein levels in HIV-positive subjects with
tuberculosis and pneumonia. Eur Respir J. 2005;25(4):688–92.
23. Nyamande K, Lalloo UG. Serum procalcitonin distinguishes CAP due to
bacteria, Mycobacterium tuberculosis and PJP. Int J Tuberc Lung Dis. 2006;
10(5):510–5.
24. Miller RF, Millar AB, Weller IVD, Semple SJG. Empirical treatment without
bronchoscopy for Pneumocystis carinii pneumonia in the acquired
immunodeficiency syndrome. Thorax. 1989;44:559–64.
25. Li WJ, Guo YL, Liu TJ, Wang K, Kong JL. Diagnosis of Pneumocystis
pneumonia using serum (1-3)-β-D-glucan: a bivariate meta-analysis and
systematic review. J Thorac Dis. 2015;7(12):2214–25.
26. Salerno D, Mushatt D, Myers L, Zhuang Y, de la Rua N, Calderon EJ, et al.
Serum and bal beta-D-glucan for the diagnosis of Pneumocystis pneumonia
in HIV postive patients. Resp Med. 2014;108:1688–95.
Mendelson et al. BMC Infectious Diseases  (2018) 18:399 Page 11 of 11
